Table 1A.
Top canonical pathways as demonstrated by interactive pathway analysis (Ingenuity System).
| M. haemolytica + BHV-1 | BHV-1 | M. haemolytica |
|---|---|---|
| 1. Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 2.51E−11*; 38/332 (0.114)a |
1. Role of Cytokines in Mediating Communication between Immune Cells 6.17E−06; 8/55 (0.145) |
1. Hepatic Fibrosis/Hepatic Stellate Cell Activation 2.41E−11; 24/146 (0.164) |
| 2. Hepatic Fibrosis/Hepatic Stellate Cell Activation 2.13E−10; 24/146 (0.164) |
2. IL-6 Signaling 8.4E−06; 11/124 (0.089) |
2. Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 1.39E−09; 33/332 (0.099) |
| 3. Triggering receptor expressed on myeloid cells 1 (TREM1) Signaling 2.13E−10; 16/71 (0.225) |
3. Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 1.02E−05; 18/332 (0.054) |
3. Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F 1.57E−09; 9/18 (0.5) |
| 4. Tumor Necrosis Factor Receptor 2 (TNFR2) Signaling 2.86E−08; 10/33 (0.303) |
4. Atherosclerosis Signaling 1.16E−05; 11/136 (0.081) |
4. Death Receptor Signaling 3.92E−09; 14/64 (0.219) |
| 5. Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 7.5E−08; 16/92 (0.174) |
5. Role of Hypercytokinemia or hyperchemokinemia in the Pathogenesis of Influenza 1.29E−05; 7/44 (0.159) |
5.TREM1 Signaling 4.99E−09; 14/71 (0.197) |
a
Target/total pathway ratio.
*
p-Value.